[{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"Viriom","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viriom \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"Viriom \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Viriom","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elsulfavirine","moa":"||NNRT","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viriom \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viriom \/ Inapplicable"},{"orgOrder":0,"company":"ChemDiv","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ChemDiv","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemDiv \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ChemDiv \/ Inapplicable"},{"orgOrder":0,"company":"Cellvera","sponsor":"Aditxt","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cellvera","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cellvera \/ Aditxt","highestDevelopmentStatusID":"15","companyTruncated":"Cellvera \/ Aditxt"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Cato Research","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Cato Research"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Fujifilm Toyama Chemical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Fujifilm Toyama Chemical","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Fujifilm Toyama Chemical"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Lind Partners"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Appili Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"15","companyTruncated":"Appili Therapeutics \/ Lind Partners"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sihuan Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sihuan Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Carelink","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carelink","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Carelink \/ Fujifilm holding","highestDevelopmentStatusID":"10","companyTruncated":"Carelink \/ Fujifilm holding"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Appili Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Appili Therapeutics"},{"orgOrder":0,"company":"CMIC Holdings","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CMIC Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CMIC Holdings \/ Fujifilm holding","highestDevelopmentStatusID":"10","companyTruncated":"CMIC Holdings \/ Fujifilm holding"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm holding \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm holding \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Toyama Chemical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Toyama Chemical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Toyama Chemical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Toyama Chemical \/ Inapplicable"},{"orgOrder":0,"company":"ChemRar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemRar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChemRar \/ Inapplicable"},{"orgOrder":0,"company":"ChemRar","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemRar \/ Russian Direct Investment Fund","highestDevelopmentStatusID":"15","companyTruncated":"ChemRar \/ Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Russian Direct Investment Fund \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Inapplicable"},{"orgOrder":0,"company":"ChemRar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ChemRar","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"ChemRar \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChemRar \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Bal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Bal Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Bal Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bal Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alkem Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"BDR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"BDR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BDR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BDR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cipla","sponsor":"Indian Institute Of Chemical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cipla \/ Indian Institute Of Chemical Technology","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Indian Institute Of Chemical Technology"},{"orgOrder":0,"company":"FDC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"FDC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"FDC \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"FDC \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Brinton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Brinton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Brinton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Brinton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Institute of Chemical Technology","sponsor":"Lasa Supergenerics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Institute of Chemical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Institute of Chemical Technology \/ Lasa Supergenerics","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Chemical Technology \/ Lasa Supergenerics"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cohance Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cohance Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cohance Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cohance Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zenara Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zenara Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Zenara Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zenara Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zenara Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Appili Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Appili Therapeutics"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Global Response Aid FZCO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Global Response Aid FZCO","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Global Response Aid FZCO"},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LAXAI Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"AiPharma","sponsor":"Appili Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.A.E","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AiPharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AiPharma \/ Appili Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"AiPharma \/ Appili Therapeutics"},{"orgOrder":0,"company":"Aditxt","sponsor":"Cellvera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aditxt \/ Cellvera","highestDevelopmentStatusID":"15","companyTruncated":"Aditxt \/ Cellvera"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Egis Pharmaceuticals PLC","sponsor":"National Institute of Pharmacy and Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HUNGARY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Egis Pharmaceuticals PLC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition","highestDevelopmentStatusID":"15","companyTruncated":"Egis Pharmaceuticals PLC \/ National Institute of Pharmacy and Nutrition"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CC-42344","moa":"||PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Favipiravir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Balflu (favipiravir) is a RNA-directed RNA polymerase inhibitor, which is approved for the treatment of patients with mild to moderate Covid-19 Infection.

                          Product Name : Balflu

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2021

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          BalPharma

                          02

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : Global Response Aid FZCO

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The data from the Kuwait CVD-04-CD-001 study involving moderate to severe COVID-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e., time to sustained hypoxia resolution) for Avigan vs. placebo.

                          Product Name : Avigan

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 27, 2021

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Global Response Aid FZCO

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          03

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Phase III

                          Sponsor : Appili Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dr. Reddy's Canada has filed an application with Health Canada on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate Covid-19 in adult patients.

                          Product Name : Avigan

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 22, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Appili Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : National Institute of Pharmacy and Nutrition

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYÉI).

                          Product Name : Favipiravir-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 20, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : National Institute of Pharmacy and Nutrition

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Egis Pharmaceuticals

                          05

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The launch is part of the global licensing agreement with FUJIFILM Toyama Chemical Co. Ltd. that grants Dr. Reddy’s the exclusive rights to manufacture, sell and distribute AVIGAN (Favipiravir) 200 mg Tablets in India.

                          Product Name : Avigan

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 19, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          06

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Ciplenza (favipiravir-generic) is a RNA-directed RNA polymerase inhibitor, small molecule, which is indicated for the treatment of patients with Covid-19 infection.

                          Product Name : Ciplenza

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Cohance

                          07

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus, the influenza virus.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 14, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Biophore

                          08

                          Details : Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.

                          Product Name : Favizen

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 08, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Biophore CB

                          09

                          Details : Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.

                          Product Name : Favizen

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 08, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Biophore CB

                          10

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : USFDA approved generic version for Favipiravir which is an antiviral medication (viral RNA polymerase inhibitor) to treat patients under their treatment for Covid-19 infections.

                          Product Name : Avigan-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 29, 2020

                          Lead Product(s) : Favipiravir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Strides Pharma Science